Abcuro Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
55
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$66M
- Investors
-
27
Abcuro General Information
Description
Developer of immunomodulatory therapeutics designed for treating both autoimmunity and cancer. The company uses proprietary analysis of transcription data from human disease to identify new approaches to target key immune system compartments, enabling healthcare professionals to plan appropriate procedures for efficient treatments.
Contact Information
Website
www.abcuro.comCorporate Office
- 55 Chapel Street
- Suite 200
- Newton, MA 02458
- United States
Corporate Office
- 55 Chapel Street
- Suite 200
- Newton, MA 02458
- United States
Abcuro Timeline
Abcuro Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series D) | 14-Aug-2026 | $66M | Completed | Clinical Trials - Phase 3 | ||
| 7. Later Stage VC (Series C) | 07-Feb-2025 | Completed | Clinical Trials - Phase 3 | |||
| 6. Secondary Transaction - Private | Completed | Clinical Trials - Phase 3 | ||||
| 5. Later Stage VC (Series B) | 11-Aug-2023 | Completed | Clinical Trials - Phase 3 | |||
| 4. Later Stage VC (Series A1) | 07-Jan-2021 | Completed | Startup | |||
| 3. Grant | 01-Jan-2019 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 09-Nov-2018 | $8M | $10.2M | Completed | Startup | |
| 1. Seed Round | 13-Dec-2016 | $2.25M | $2.25M | Completed | Startup |
Abcuro Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D1 | ||||||||
| Series D | ||||||||
| Series C-1 | ||||||||
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A1 | ||||||||
| Series A | 1,619,201 | $0.001000 | $4.94 | $4.94 | 1x | $4.94 | 0.65% | |
| Seed | 671,141 | $0.001000 | $3.35 | $3.35 | 1x | $3.35 | 0.27% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Abcuro Comparisons
Industry
Financing
Details
Abcuro Competitors (6)
One of Abcuro’s 6 competitors is Agenus, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Alector | Formerly VC-backed | South San Francisco, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Atara Biotherapeutics | Formerly VC-backed | Thousand Oaks, CA | ||||
| Incyte | Formerly VC-backed | Wilmington, DE |
Abcuro Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Abcuro Patents
Abcuro Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4836987-A1 | Methods of treating inclusion body myositis (ibm) | Pending | 02-Jan-2025 | ||
| WO-2026072990-A1 | Methods of treating t-cell large granular lymphocytic leukemia | Pending | 27-Sep-2024 | ||
| AU-2025205871-A1 | Methods of treating inclusion body myositis (ibm) | Active | 02-Jan-2024 | ||
| AU-2025205871-C1 | Methods of treating inclusion body myositis (ibm) | Active | 02-Jan-2024 | ||
| WO-2025147544-A1 | Methods of treating inclusion body myositis (ibm) | Inactive | 02-Jan-2024 | C07K16/2851 |
Abcuro Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Abcuro Investors (27)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| abrdn Healthcare Investors | Hedge Fund | Minority | ||
| Abrdn Healthcare Opportunities Fund | Mutual Fund | Minority | ||
| Angel (individual) | Minority | |||
| Rock Springs Capital | Venture Capital | Minority | ||
| Angel (individual) | Minority |
Abcuro FAQs
-
When was Abcuro founded?
Abcuro was founded in 2015.
-
Where is Abcuro headquartered?
Abcuro is headquartered in Newton, MA.
-
What is the size of Abcuro?
Abcuro has 55 total employees.
-
What industry is Abcuro in?
Abcuro’s primary industry is Drug Discovery.
-
Is Abcuro a private or public company?
Abcuro is a Private company.
-
What is the current valuation of Abcuro?
The current valuation of Abcuro is .
-
What is Abcuro’s current revenue?
The current revenue for Abcuro is .
-
How much funding has Abcuro raised over time?
Abcuro has raised $473M.
-
Who are Abcuro’s investors?
abrdn Healthcare Investors, Abrdn Healthcare Opportunities Fund, , Rock Springs Capital, and are 5 of 27 investors who have invested in Abcuro.
-
Who are Abcuro’s competitors?
Agenus, Alector, Kite Pharma, Atara Biotherapeutics, and Incyte are some of the 6 competitors of Abcuro.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
